Search

Your search keyword '"Van Den Broek A.J."' showing total 9 results
Start Over Author "Van Den Broek A.J."
9 results on '"Van Den Broek A.J."'

2. 1133P Whole genome sequencing can classify diagnostically challenging tumors

Author

Schipper, L.J., primary, Snaebjornsson, P., additional, Samsom, K.G., additional, Bosch, L.J.W., additional, Lalezari, F., additional, Priestley, P., additional, Shale, C., additional, Jacobs, N., additional, van den Broek, A.J., additional, Roepman, P., additional, van der Hoeven, J.J.M., additional, Steeghs, N., additional, Cuppen, E., additional, Meijer, G., additional, Voest, E.E., additional, and Monkhorst, K., additional

Published
2021
Full Text
View/download PDF

3. Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts.

Author

Smit V.T.H.B.M., Pharoah P.D.P., Shah M., Siesling S., Southey M.C., Schmidt M.K., Hooning M.J., Westenend P.J., Wendt C., Wang Q., Van't Veer L.J., van Ongeval C., van Leeuwen F.E., van Deurzen C.H.M., van den Broek A.J., Tollenaar R.A.E.M., Tapper W.J., Giardiello D., Hauptmann M., Steyerberg E.W., Adank M.A., Akdeniz D., Blom J.C., Blomqvist C., Bojesen S.E., Bolla M.K., Brinkhuis M., Chang-Claude J., Czene K., Devilee P., Dunning A.M., Easton D.F., Eccles D.M., Fasching P.A., Figueroa J., Flyger H., Garcia-Closas M., Haeberle L., Haiman C.A., Hall P., Hamann U., Hopper J.L., Jager A., Jakubowska A., Jung A., Keeman R., Koppert L.B., Kramer I., Lambrechts D., Le Marchand L., Lindblom A., Lubinski J., Manoochehri M., Mariani L., Nevanlinna H., Oldenburg H.S.A., Pelders S., Smit V.T.H.B.M., Pharoah P.D.P., Shah M., Siesling S., Southey M.C., Schmidt M.K., Hooning M.J., Westenend P.J., Wendt C., Wang Q., Van't Veer L.J., van Ongeval C., van Leeuwen F.E., van Deurzen C.H.M., van den Broek A.J., Tollenaar R.A.E.M., Tapper W.J., Giardiello D., Hauptmann M., Steyerberg E.W., Adank M.A., Akdeniz D., Blom J.C., Blomqvist C., Bojesen S.E., Bolla M.K., Brinkhuis M., Chang-Claude J., Czene K., Devilee P., Dunning A.M., Easton D.F., Eccles D.M., Fasching P.A., Figueroa J., Flyger H., Garcia-Closas M., Haeberle L., Haiman C.A., Hall P., Hamann U., Hopper J.L., Jager A., Jakubowska A., Jung A., Keeman R., Koppert L.B., Kramer I., Lambrechts D., Le Marchand L., Lindblom A., Lubinski J., Manoochehri M., Mariani L., Nevanlinna H., Oldenburg H.S.A., and Pelders S.

Abstract

Background: Three tools are currently available to predict the risk of contralateral breast cancer (CBC). We aimed to compare the performance of the Manchester formula, CBCrisk, and PredictCBC in patients with invasive breast cancer (BC). Method(s): We analyzed data of 132,756 patients (4682 CBC) from 20 international studies with a median follow-up of 8.8 years. Prediction performance included discrimination, quantified as a time-dependent Area-Under-the-Curve (AUC) at 5 and 10 years after diagnosis of primary BC, and calibration, quantified as the expected-observed (E/O) ratio at 5 and 10 years and the calibration slope. Result(s): The AUC at 10 years was: 0.58 (95% confidence intervals [CI] 0.57-0.59) for CBCrisk; 0.60 (95% CI 0.59-0.61) for the Manchester formula; 0.63 (95% CI 0.59-0.66) and 0.59 (95% CI 0.56-0.62) for PredictCBC-1A (for settings where BRCA1/2 mutation status is available) and PredictCBC-1B (for the general population), respectively. The E/O at 10 years: 0.82 (95% CI 0.51-1.32) for CBCrisk; 1.53 (95% CI 0.63-3.73) for the Manchester formula; 1.28 (95% CI 0.63-2.58) for PredictCBC-1A and 1.35 (95% CI 0.65-2.77) for PredictCBC-1B. The calibration slope was 1.26 (95% CI 1.01-1.50) for CBCrisk; 0.90 (95% CI 0.79-1.02) for PredictCBC-1A; 0.81 (95% CI 0.63-0.99) for PredictCBC-1B, and 0.39 (95% CI 0.34-0.43) for the Manchester formula. Conclusion(s): Current CBC risk prediction tools provide only moderate discrimination and the Manchester formula was poorly calibrated. Better predictors and re-calibration are needed to improve CBC prediction and to identify low- and high-CBC risk patients for clinical decision-making.Copyright © 2020, Springer Science+Business Media, LLC, part of Springer Nature.

Published
2020

4. Prediction and clinical utility of a contralateral breast cancer risk model.

Author

Wendt C., Van Leeuwen F.E., Van Ongeval C., Van't Veer L.J., Wang Q., Westenend P.J., Schmidt M.K., Hooning M.J., Giardiello D., Steyerberg E.W., Hauptmann M., Adank M.A., Akdeniz D., Blomqvist C., Bojesen S.E., Bolla M.K., Brinkhuis M., Chang-Claude J., Czene K., Devilee P., Dunning A.M., Easton D.F., Eccles D.M., Fasching P.A., Figueroa J., Flyger H., Garcia-Closas M., Haeberle L., Haiman C.A., Hall P., Hamann U., Hopper J.L., Jager A., Jakubowska A., Jung A., Keeman R., Kramer I., Lambrechts D., Le Marchand L., Lindblom A., Lubinski J., Manoochehri M., Mariani L., Nevanlinna H., Oldenburg H.S.A., Pelders S., Pharoah P.D.P., Shah M., Siesling S., Smit V.T.H.B.M., Southey M.C., Tapper W.J., Tollenaar R.A.E.M., Van Den Broek A.J., Van Deurzen C.H.M., Wendt C., Van Leeuwen F.E., Van Ongeval C., Van't Veer L.J., Wang Q., Westenend P.J., Schmidt M.K., Hooning M.J., Giardiello D., Steyerberg E.W., Hauptmann M., Adank M.A., Akdeniz D., Blomqvist C., Bojesen S.E., Bolla M.K., Brinkhuis M., Chang-Claude J., Czene K., Devilee P., Dunning A.M., Easton D.F., Eccles D.M., Fasching P.A., Figueroa J., Flyger H., Garcia-Closas M., Haeberle L., Haiman C.A., Hall P., Hamann U., Hopper J.L., Jager A., Jakubowska A., Jung A., Keeman R., Kramer I., Lambrechts D., Le Marchand L., Lindblom A., Lubinski J., Manoochehri M., Mariani L., Nevanlinna H., Oldenburg H.S.A., Pelders S., Pharoah P.D.P., Shah M., Siesling S., Smit V.T.H.B.M., Southey M.C., Tapper W.J., Tollenaar R.A.E.M., Van Den Broek A.J., and Van Deurzen C.H.M.

Abstract

Background: Breast cancer survivors are at risk for contralateral breast cancer (CBC), with the consequent burden of further treatment and potentially less favorable prognosis. We aimed to develop and validate a CBC risk prediction model and evaluate its applicability for clinical decision-making. Method(s): We included data of 132,756 invasive non-metastatic breast cancer patients from 20 studies with 4682 CBC events and a median follow-up of 8.8 years. We developed a multivariable Fine and Gray prediction model (PredictCBC-1A) including patient, primary tumor, and treatment characteristics and BRCA1/2 germline mutation status, accounting for the competing risks of death and distant metastasis. We also developed a model without BRCA1/2 mutation status (PredictCBC-1B) since this information was available for only 6% of patients and is routinely unavailable in the general breast cancer population. Prediction performance was evaluated using calibration and discrimination, calculated by a time-dependent area under the curve (AUC) at 5 and 10 years after diagnosis of primary breast cancer, and an internal-external cross-validation procedure. Decision curve analysis was performed to evaluate the net benefit of the model to quantify clinical utility. Result(s): In the multivariable model, BRCA1/2 germline mutation status, family history, and systemic adjuvant treatment showed the strongest associations with CBC risk. The AUC of PredictCBC-1A was 0.63 (95% prediction interval (PI) at 5 years, 0.52-0.74; at 10 years, 0.53-0.72). Calibration-in-the-large was-0.13 (95% PI:-1.62-1.37), and the calibration slope was 0.90 (95% PI: 0.73-1.08). The AUC of Predict-1B at 10 years was 0.59 (95% PI: 0.52-0.66); calibration was slightly lower. Decision curve analysis for preventive contralateral mastectomy showed potential clinical utility of PredictCBC-1A between thresholds of 4-10% 10-year CBC risk for BRCA1/2 mutation carriers and non-carriers. Conclusion(s): We developed a reasonab

Published
2020

5. Reproductive profiles and risk of breast cancer subtypes

Author

Brouckaert, O. (Olivier), Rudolph, A. (Anja), Laenen, A. (Annouschka), Keeman, J.N., Bolla, M.K. (Manjeet K.), Wang, Q. (Qin), Soubry, A. (Adelheid), Wildiers, H. (Hans), Andrulis, I.L. (Irene), Arndt, V. (Volker), Beckmann, M.W. (Matthias), Benítez, J. (Javier), Blomqvist, C. (Carl), Bojesen, S.E. (Stig), Brauch, H. (Hiltrud), Brennan, P. (Paul), Brenner, H. (Hermann), Chenevix-Trench, G. (Georgia), Choi, J.-Y. (Ji-Yeob), Cornelissen, S. (Sten), Couch, F.J. (Fergus J.), Cox, A. (Angela), Cross, S.S. (Simon S.), Czene, K. (Kamila), Eriksson, M. (Mats), Fasching, P.A. (Peter), Figueroa, J.D. (Jonine), Flyger, H. (Henrik), Giles, G.G. (Graham G.), González-Neira, A. (Anna), Guénel, P. (Pascal), Hall, P. (Per), Hollestelle, A. (Antoinette), Hopper, J.L. (John), Ito, H. (Hidemi), Jones, M. (Michael), Kang, D. (Daehee), Knight, J.A. (Julia), Kosma, V-M. (Veli-Matti), Li, J. (Jingmei), Lindblom, A. (Annika), Lilyquist, J. (Jenna), Lophatananon, A. (Artitaya), Mannermaa, A. (Arto), Manoukian, S. (Siranoush), Margolin, S. (Sara), Matsuo, K. (Keitaro), Muir, K.R. (K.), Nevanlinna, H. (Heli), Peterlongo, P. (Paolo), Pykäs, K. (Katri), Saajrang, S. (Suleeporn), Seynaeve, C.M. (Caroline), Shen, C.-Y. (Chen-Yang), Shu, X.-O. (Xiao-Ou), Southey, M.C. (Melissa C.), Swerdlow, A.J. (Anthony ), Teo, S.H. (Soo Hwang), Tollenaar, R.A.E.M. (Rob), Truong, T. (Thérèse), Tseng, C.-C. (Chiu-Chen), van den Broek, A.J. (Alexandra J.), Deurzen, C.H.M. (Carolien) van, Winqvist, R. (Robert), Wu, A.H. (Anna), Yip, C.H. (Cheng Har), Yu, J.-C. (Jyh-Cherng), Zheng, W. (Wei), Milne, R.L. (Roger), Pharoah, P.D.P. (Paul), Easton, D.F. (Douglas), Schmidt, M.K. (Marjanka), García-Closas, M. (Montserrat), Chang-Claude, J. (Jenny), Lambrechts, D. (Diether), Neven, P. (Patrick), Brouckaert, O. (Olivier), Rudolph, A. (Anja), Laenen, A. (Annouschka), Keeman, J.N., Bolla, M.K. (Manjeet K.), Wang, Q. (Qin), Soubry, A. (Adelheid), Wildiers, H. (Hans), Andrulis, I.L. (Irene), Arndt, V. (Volker), Beckmann, M.W. (Matthias), Benítez, J. (Javier), Blomqvist, C. (Carl), Bojesen, S.E. (Stig), Brauch, H. (Hiltrud), Brennan, P. (Paul), Brenner, H. (Hermann), Chenevix-Trench, G. (Georgia), Choi, J.-Y. (Ji-Yeob), Cornelissen, S. (Sten), Couch, F.J. (Fergus J.), Cox, A. (Angela), Cross, S.S. (Simon S.), Czene, K. (Kamila), Eriksson, M. (Mats), Fasching, P.A. (Peter), Figueroa, J.D. (Jonine), Flyger, H. (Henrik), Giles, G.G. (Graham G.), González-Neira, A. (Anna), Guénel, P. (Pascal), Hall, P. (Per), Hollestelle, A. (Antoinette), Hopper, J.L. (John), Ito, H. (Hidemi), Jones, M. (Michael), Kang, D. (Daehee), Knight, J.A. (Julia), Kosma, V-M. (Veli-Matti), Li, J. (Jingmei), Lindblom, A. (Annika), Lilyquist, J. (Jenna), Lophatananon, A. (Artitaya), Mannermaa, A. (Arto), Manoukian, S. (Siranoush), Margolin, S. (Sara), Matsuo, K. (Keitaro), Muir, K.R. (K.), Nevanlinna, H. (Heli), Peterlongo, P. (Paolo), Pykäs, K. (Katri), Saajrang, S. (Suleeporn), Seynaeve, C.M. (Caroline), Shen, C.-Y. (Chen-Yang), Shu, X.-O. (Xiao-Ou), Southey, M.C. (Melissa C.), Swerdlow, A.J. (Anthony ), Teo, S.H. (Soo Hwang), Tollenaar, R.A.E.M. (Rob), Truong, T. (Thérèse), Tseng, C.-C. (Chiu-Chen), van den Broek, A.J. (Alexandra J.), Deurzen, C.H.M. (Carolien) van, Winqvist, R. (Robert), Wu, A.H. (Anna), Yip, C.H. (Cheng Har), Yu, J.-C. (Jyh-Cherng), Zheng, W. (Wei), Milne, R.L. (Roger), Pharoah, P.D.P. (Paul), Easton, D.F. (Douglas), Schmidt, M.K. (Marjanka), García-Closas, M. (Montserrat), Chang-Claude, J. (Jenny), Lambrechts, D. (Diether), and Neven, P. (Patrick)

Abstract

__Background:__ Previous studies have shown that reproductive factors are differentially associated with breast cancer (BC) risk by subtypes. The aim of this study was to investigate associations between reproductive factors and BC subtypes, and whether these vary by age at diagnosis. __Methods:__ We used pooled data on tumor markers (estrogen and progesterone receptor, human epidermal growth factor receptor-2 (HER2)) and reproductive risk factors (parity, age at first full-time pregnancy (FFTP) and age at menarche) from 28,095 patients with invasive BC from 34 studies participating in the Breast Cancer Association Consortium (BCAC). In a case-only analysis, we used logistic regression to assess associations between reproductive factors and BC subtype compared to luminal A tumors as a reference. The interaction between age and parity in BC subtype risk was also tested, across all ages and, because age was modeled non-linearly, specifically at ages 35, 55 and 75 years. __Results:__ Parous women were more likely to be diagnosed with triple negative BC (TNBC) than with luminal A BC, irrespective of age. Parous women were also more likely to be diagnosed with luminal and non-luminal HER2-like BCs and this effect was slightly more pronounced at an early age. For instance, women diagnosed at age 35 were 1.48 more likely to have luminal HER2-like BC than luminal A BC, while this association was not significant at age 75. While age at menarche was not significantly associated with BC subtype, increasing age at FFTP was non-linearly associated with TNBC relative to luminal A BC. An age at FFTP of 25 versus 20 years lowered the risk for TNBC, but this effect was not apparent at a later FFTP. __Conclusions:__ Our main findings suggest that parity is associated with TNBC across all ages at BC diagnosis, whereas the association with luminal HER2-like BC was present only for early onset BC.

Published
2017
Full Text
View/download PDF

7. Late presentatie van aangeboren hernia diaphragmatica

Author

van den Broek, A.J., Gemke, R.J.B.J., Bos, A.P., Heij, H.A., Other departments, Other Research, Paediatric Intensive Care, Paediatric Surgery, and Philosophy

Abstract

A boy aged 6 months and a girl aged 9 months were admitted due to vomiting, among others, and a boy aged 11 months due to pneumonia. It turned out that they had a congenital diaphragmatic hernia. Primary operative repair was performed successfully in all patients, followed by recovery. The older boy experienced a relapse nearly 1 year later, which was treated by surgical correction. Most congenital diaphragmatic hernias present directly after birth, with cyanosis and respiratory distress. However, 10-20% of the cases are discovered after this period. In these children diagnosis can be difficult because of the diverse symptoms such as vomiting, feeding difficulties, tachypnoea or recurrent respiratory tract infections. Physical signs include the absence of breath sounds or the presence of bowel sounds in the chest. Chest X-ray, contrast upper gastrointestinal series or ultrasound imaging confirms the diagnosis. Delay in treatment can lead to complications such as necrosis of the bowel. In young children with acute or chronic respiratory infections or gastrointestinal complaints, a congenital diaphragmatic defect should be considered

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results